One Clinical Dossier, 27 Member States: How the EU Joint Clinical Assessment Is Changing Drug Launches?

For years, launching a new medicine in Europe meant answering the same clinical question again and again. Each country’s health technology assessment (HTA) body reviewed largely the same trial data, applied its own comparators, and worked on its own timeline. But how can one clinical evidence package support consistent assessment across multiple European markets without repeating the same work country by country? The Joint Clinical Assessment (JCA) was introduced to end that monotonous work. 

A JCA is a harmonised single assessment across the European Union (EU) comparing the clinical effectiveness and safety of the new medicine to the relevant alternatives. In short, it is a comprehensive report generated by HTA bodies across MS under the EU HTA Regulation (Regulation (EU) 2021/2282). It involves the submission of one dossier by the developer, built around a common set of questions agreed across countries, and one report is generated for national HTA bodies for further development. However, price or access is not established by the JCA. Decisions regarding economic evaluation, pricing, and access remain within the individual Member States. 

That distinction matters, because the JCA is no longer a policy topic. It is a live, time-bound workstream inside the launch plan of every new oncology active substance and advanced therapy medicinal product (ATMP) filed with the European Medicines Agency (EMA) since January 2025.

In this article, we’ve answered: 

• Why does Europe need a Joint Clinical Assessment? 

• How does the JCA process work, from scoping to report? 

• How can the JCA help pharma and biotech companies launch? 

• What does the first JCA report teach sponsors about evidence? 

• How are national HTA agencies adapting to the JCA? 

• What challenges could affect JCA implementation across Europe? 

• How should pharma and biotech teams prepare for the JCA? 

Why Did Europe Need a Joint Clinical Assessment? 

Europe is one regulatory market but 27 separate access markets. The EMA recommends a medicine for authorisation once, yet reimbursement only follows after each country decides for itself whether to fund it. Before the Joint Clinical Assessment, that meant sponsors prepared national submissions around the same pivotal trials, each shaped by local templates, local comparators and local timelines. 

Three problems followed. The first was duplication, with many HTA bodies re-reviewing the same clinical evidence. The second was divergence: the same product could receive different clinical conclusions in different countries, sometimes reflecting the choice of comparator and method as much as the data. The third was delay: patients in some countries waited longer simply because their national process started later or ran slower. 

Voluntary cooperation had already helped. Years of joint work under EUnetHTA prepared the ground for shared methods. But it could not guarantee that every country would use one assessment. The Regulation turns that cooperation into law, introducing a single EU-level submission file, pooled resources, no duplicate national assessments, stronger scientific quality, and a 30-day completion target after authorisation.

How Does a JCA Work in Practice?

The process runs alongside the EMA’s review, and the clock is short. 

• Scoping. Member States submit their Population, Intervention, Comparator, and Outcome (PICO) questions, which are consolidated into a single assessment scope.  

• Dossier. The developer has about 100 days after the scope is issued (60 in accelerated procedures and certain variations), and never later than 45 days before the EMA’s CHMP opinion. 

• Assessment. An assessor and co-assessor from different Member States draft the report, with input from patients and clinical experts, and the developer checks it for factual accuracy.  

• Report. The HTACG endorses the report no later than 30 days after the Commission grants marketing authorisation, and it is published after a procedural check. 

Scoping is where the Joint Clinical Assessment becomes a strategic issue. Comparators that differ by country do not disappear; they are consolidated into the scope. A review of 35 PICO exercises found an average of eight consolidated PICOs, yet one simulation for a first-line immuno-oncology treatment in metastatic lung cancer produced 67, reflecting the views of 25 countries. So how many questions will your dossier need to answer? Nobody knows for certain until the scope arrives, which is why preparation cannot wait for it. 

Two points are worth holding onto. The JCA assesses relative effects against the comparators in the scope, not whichever control arm the pivotal trial used. And it stays clinical: it reports what the evidence shows and how certain it is.

How Is the JCA Helping Pharma and Biotech Companies Launch Successfully? 

Read as an added hurdle, the Joint Clinical Assessment looks like more work. Read as system design, it is built to remove several frictions that have historically slowed European launches. We see four places where sponsors stand to benefit. 

One dossier that travels – Sponsors typically prepared a separate dossier for each country. The JCA replaces the clinical part of that work with one EU-level submission, and national bodies annex both the dossier and the published report to their own documentation. Germany and France have already started incorporating JCA reports into national procedures and cutting duplicate clinical submissions, so evidence built once now does more work. 

A report that lands within a month of authorisation – Because the JCA runs alongside the EMA review, the report is due within 30 days of the marketing authorisation, which is meant to speed up national pricing and reimbursement decisions. For tovorafenib, the Commission granted conditional authorisation on 22 April 2026 and the HTACG endorsed the report on 30 April. National discussions can begin from a documented clinical position instead of waiting for one. 

Early clarity on what will be judged – The scope tells a developer which comparators and outcomes matter before the dossier is written, and the developer can request a meeting with the JCA subgroup once it receives the scope. Earlier still, joint scientific consultations (JSCs) let developers seek advice from Member States on their evidence-generation plans. They are offered without fees in 2026, but with only 8 to 12 planned for medicines, places are limited. 

One methodological standard, with patient input built in – HTACG guidance sets common methodological expectations, which is easier to design for than 27 different national preferences. Patients and clinicians are consulted systematically while the assessment is prepared, so patient-relevant outcomes reach the table early. 

None of this is automatic. Implementation is still early, and the benefits above go to sponsors who arrive prepared. The first report shows why.

What Did the First JCA Teach Us? 

Tovorafenib is a useful case because it was a demanding test. Its pivotal study, FIREFLY-1, is a non-comparative phase 2 trial. The consolidated scope held eight PICOs, and the developer submitted comparative results for two. One, an unanchored matching-adjusted indirect comparison (MAIC) against dabrafenib plus trametinib, made it into the report. The other was excluded because its comparator study was documented only in conference abstracts. The remaining six went unassessed because no comparator data existed for the target population. 

Even the comparison that reached the report carried what the assessors called major uncertainties: a small effective sample size, confounders that could not be adjusted for, and estimates that should not necessarily be read as causal effects. This is not a verdict on the medicine, which already held conditional authorisation. It shows how far a non-comparative dataset can travel in a comparative assessment, and it raises a fair feasibility question: in rare diseases such as this one, comparator arms can be unethical and alternative data may not exist, and the sponsor itself noted that comparative evidence is hard to build where no standard of care exists. 

Three lessons stand out. 

• Comparators come from the scope, not from your trial – A design that satisfies the regulator can still leave most PICOs unanswered. 

• Indirect comparisons need planning, not improvisation – The assessors pointed to shortcomings in how confounders were identified and to missing comparator data needed for adjustment. Both are easier to address well before the dossier clock starts. 

• Evidence has to be publication-grade – A comparator study reported only in abstracts was excluded, and the assessors declined the developer’s argument that rarity justified an exception.

The JCA makes evidence strategy more critical than ever. Explore our guide to Building a Global Evidence Strategy for Overseas Reimbursement Success.

How Are National HTA Agencies Adapting to the JCA? 

The implementation of the JCA is not limited to changes regarding the EU-level clinical assessment. The national HTA agencies adapt their guidance and submission requirements and assessment processes to incorporate the JCA outputs. 

The pace and extent of adaptations differ across countries. For example, Germany and France implemented more thorough adaptations to their assessment procedures to include the JCA reports and to avoid duplication of clinical evidence submissions. While other agencies introduced only limited procedural adaptations or are still working on incorporating JCA outputs into national processes. 

 Table 2: Examples of HTA agencies that have recently adapted national guidance and processes following implementation of the EU JCA since 2025. 

Abbreviations: AIFA, Italian Medicines Agency; DMC, Danish Medicines Council; G-BA, Federal Joint Committee; HAS, French National Authority for Health; HTAR, Regulation (EU) 2021/2282 on Health Technology Assessment; HTD, health technology developer; JSC, Joint Scientific Consultation; NOMA, Norwegian Medical Products Agency; P&R, pricing and reimbursement; TLV, Dental and Pharmaceutical Benefits Agency 

The EU HTA Regulation also establishes an important principle for developers: information, data, and analyses already provided at EU level need not be submitted again at national level. This avoids duplication, while ensuring that national responsibility for pricing, reimbursement and access remains with Member States.

What Challenges Are Emerging as the JCA Takes Effect? 

The JCA is still in its early stages, and implementation across Europe raises operational, methodological, and governance challenges. Some affect HTA agencies directly; others have implications for how developers generate and organise evidence. 

PICO complexity across countries

The breadth of PICO definitions can make it difficult to establish a common assessment scope across Member States. Differences in treatment availability, nationally licensed indications, and clinical practice, including off-label use, can lead to large numbers of potential comparators. Members of IQWiG have noted that approximately one-third of requested comparators are not available across all jurisdictions. As the number of PICOs increases, assessments may become more complex and conclusions may become harder to interpret for national decision-making. 

Earlier evidence requirements and lifecycle uncertainty

Running the JCA alongside regulatory assessment increases the pressure to generate comparative and HTA-relevant evidence earlier in clinical development. Developers may also face uncertainty about how follow-up evidence should be generated after the initial assessment. The HTAR does not specify how this evidence should be generated or provide mechanisms to mandate further data collection. National bodies may therefore need to conduct reassessments as additional evidence emerges. Joint Scientific Consultations could provide an opportunity to discuss evidence-generation plans earlier and take a more lifecycle-based approach. 

Resource and operational capacity

Delivering JCAs within compressed timelines requires substantial methodological and operational capacity from HTA agencies acting as assessors and co-assessors. Smaller agencies may face constraints in staffing, specialist expertise, and resource allocation as the number of assessments increases. Sustainable resourcing, technical support, and balanced participation across Member States will therefore remain important to maintaining assessment quality and timely delivery.

How Should Pharma & Biotech Teams Prepare? 

Because the formal window is short, much of the work has to happen before it opens. Four moves matter most. 

• Model the likely PICOs early – Bring medical affairs, HEOR, market access and local affiliates together to map the comparators and populations each target country is likely to request, well before filing. 

• Plan the indirect comparison alongside the trial – Where head-to-head data are unlikely, decide early whether an anchored network meta-analysis or a population-adjusted method fits, and secure the patient-level data and comparator sources it needs. 

• Use a joint scientific consultation while the design is open – It lets you test an evidence plan with HTA bodies before a well-run trial answers the wrong comparator question. 

• Prepare the 100-day workflow in advance – Agree ownership, review steps and templates before the scope arrives, so, the window is spent on execution, not on reconciling open decisions. 

Preparation does not end at launch: the framework provides for updates to JCA reports, and new comparators, evidence or markets can reopen the evidence question.

What Does the Future of the JCA Look Like? 

Implementation of the EU JCA remains at an early stage, and its ability to achieve its intended objectives has yet to be determined. To date, 15 JCAs have been initiated, while the HTACG Annual Work Programme 2026 indicates a substantial increase in future activity. 

The publication of the first JCA report, conducted by NCPE in Ireland and IQWiG in Germany, provides an important practical test of how JCA methodologies, evidence requirements, and assessment processes work in practice. 

As more JCAs are completed and incorporated into national processes, greater clarity should emerge on three questions: how JCA outputs are interpreted nationally, how much duplication they remove from national assessments, and how effectively they support more consistent and efficient clinical assessment across Europe. 

For pharma and biotech companies, the direction is already clear. The JCA needs to be considered as part of evidence planning well before the formal submission window opens.

How Can IeB Help You Prepare for the JCA? 

We work with pharma and biotech teams as a strategic partner on European market access. For the Joint Clinical Assessment, that means helping teams anticipate likely PICO scenarios, prioritise evidence gaps by reimbursement risk, sequence evidence plans across markets, and align medical affairs, HEOR, regulatory and market access around one roadmap. If you are planning an EU filing, we would be glad to talk through where your evidence stands. 

Let’s talk strategy! 

Fill out the form below or email us at contact@iebrain.com to have a quick conversation with our pharma and healthcare consultants.